Xlife Sciences AG (XSWX:XLS) Other Income (Expense): CHF-0.11 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:XLS Xlife Sciences AG XSWX:XLS
37 GF Score
Price CHF16.30
GF Value CHF7.07
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG Other Income (Expense)?

Xlife Sciences AG XSWX:XLS +5.84% 37 Other Income (Expense) is CHF-0.11 Mil as of Dec. 2025. GuruFocus rates XSWX:XLS with a GF Score™ of 37/100 and a GF Value™ of CHF7.07 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Xlife Sciences AG's other income expense for the Xlife Sciences AG's pretax income for the six months ended in Dec. 2025 was CHF-1.59 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-0.11 Mil.

Xlife Sciences AG  (XSWX:XLS) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Xlife Sciences AG Other Income (Expense) Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG Other Income (Expense) Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Income (Expense)
Get a 7-Day Free Trial 58.82 25.50 25.20 43.41 -0.11

Xlife Sciences AG Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.96 4.93 38.48 1.48 -1.59
XSWX:XLS
37GF Score
Xlife Sciences AG XSWX:XLS
Other Income (Expense) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xlife Sciences AG Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-0.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Income (Expense) →
What does a Other Income (Expense) of CHF-0.11 Mil mean?
Xlife Sciences AG (XSWX:XLS) has a Other Income (Expense) of CHF-0.11 Mil as of Dec. 2025. Other income and expenses that a company records on the income statement. View historical data on Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's Other Income (Expense) too high?
Xlife Sciences AG's current Other Income (Expense) is CHF-0.11 Mil. Overall, Xlife Sciences AG has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Other Income (Expense) compare to VRTX and REGN?
Xlife Sciences AG's Other Income (Expense) of CHF-0.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Income (Expense) for a Biotechnology company?
A good Other Income (Expense) depends on the Biotechnology industry context. However, Other Income (Expense) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Income (Expense) mean?
A high Other Income (Expense) can signal that a stock is expensive relative to its fundamentals. Other income and expenses that a company records on the income statement. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Other Income (Expense) is CHF-0.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.07, compared to a current price of CHF16.30 — trading 130.6% above its estimated fair value. The current Other Income (Expense) is CHF-0.11 Mil. Xlife Sciences AG's overall GF Score™ is 37/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Income (Expense) calculated?
Other Income (Expense) is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Other Income (Expense) is CHF-0.11 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of CHF16.30 is trading 130.6% above its estimated GF Value™ of CHF7.07. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for XSWX:XLS:

  • Other Income (Expense): CHF-0.11 Mil
  • GF Value™: CHF7.07 vs. price of CHF16.30 (130.6% above fair value)
  • GF Score™: 37/100 with 10 warning signs

No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Germany
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
37GF Score

Get the complete analysis for XSWX:XLS

Other Income (Expense) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF16.30
Price
CHF7.07
GF Value